Reading view
SEA-Eval: A Benchmark for Evaluating Self-Evolving Agents Beyond Episodic Assessment
JAEGER: Joint 3D Audio-Visual Grounding and Reasoning in Simulated Physical Environments
Data Difficulty and the Generalization--Extrapolation Tradeoff in LLM Fine-Tuning
FDX1 as a predictive biomarker and therapeutic target for lymph node metastasis in gastric cancer
Clin Exp Med. 2026 May 10. doi: 10.1007/s10238-026-02160-0. Online ahead of print.
ABSTRACT
The prognostic values of cuproptosis-related genes (CRGs) in gastric cancer with lymph node metastasis (GCLM), especially in the tumor immune microenvironment (TIME), remain unclear. We analyzed the expression, mutation, immunity, drug sensitivity, and prognostic value of CRGs in GCLM using TCGA and GEO cohorts. Consensus clustering was performed to identify CRG subtypes, with differences characterized by multi-omics analysis. A CRG-based prognostic risk score and immune score were constructed for individualized assessment, and the role of CRGs was validated through in vitro and in vivo experiments. Consensus clustering revealed that CRGs were significantly enriched in biological processes related to mitosis and energy metabolism, as well as in immune-related and cancer-associated pathways. Four distinct CRG subtypes were identified, showing marked differences in expression profiles, prognosis, genetic alterations, TIME, and chemotherapeutic drug sensitivity. We developed an exploratory CRG-based prognostic risk score for preliminary individualized assessment, and the functional relevance of CRGs in GCLM was further validated through in vitro experiments. Among these, FDX1, LIAS, DLAT, MTF1, and GLS were identified as key determinants of overall survival in patients with GCLM, with FDX1 emerging as a potential independent prognostic factor. Notably, upregulation of FDX1 significantly suppressed lymph node metastasis of gastric cancer cells in a mouse popliteal lymph node metastasis model. Our data uncovers FDX1 might be a potential favorable prognostic factors in GCLM patients. These findings may improve our understanding of CRGs in GCLM and provide new in-sights for assessing prognosis and developing more effective treatment strategies.
PMID:42107026 | DOI:10.1007/s10238-026-02160-0
ActionNex: A Virtual Outage Manager for Cloud
Schema-Aware Planning and Hybrid Knowledge Toolset for Reliable Knowledge Graph Triple Verification
Diagonal-Tiled Mixed-Precision Attention for Efficient Low-Bit MXFP Inference
ROSClaw: A Hierarchical Semantic-Physical Framework for Heterogeneous Multi-Agent Collaboration
Mind Your HEARTBEAT! Claw Background Execution Inherently Enables Silent Memory Pollution
Grounded Token Initialization for New Vocabulary in LMs for Generative Recommendation
Multidimensional evaluation of large language models in radiology report readability
npj Digital Medicine, Published online: 01 April 2026; doi:10.1038/s41746-026-02589-3
Multidimensional evaluation of large language models in radiology report readabilityATP-Bench: Towards Agentic Tool Planning for MLLM Interleaved Generation
MultiGen: Level-Design for Editable Multiplayer Worlds in Diffusion Game Engines
QuestA: Expanding Reasoning Capacity in LLMs via Question Augmentation
Targeting sialic acid metabolism: a therapeutic strategy against gastric cancer driven by WZ35
Cell Oncol (Dordr). 2026 Mar 23;49(2):60. doi: 10.1007/s13402-026-01194-6.
ABSTRACT
Glycolytic reprogramming is closely associated with the occurrence and progression of gastric cancer. Specifically, the energy derived from glucose metabolism and the cellular proteins by its intermediate products influence gastric cancer development. However, as an important branch of glucose metabolism, sialic acid metabolism and its mediated sialylation modifications remain insufficiently studied in gastric cancer, and their specific relationship with malignant tumor progression requires further exploration. This study employed a multi‑omics approach, integrating metabolomics, single‑cell RNA sequencing, and bulk RNA sequencing analyses, to investigate the metabolic landscape of gastric cancer and its associated alterations. The results indicated that sialic acid is a characteristic metabolite in malignant gastric cancer tissues. It modulates biological functions such as immune response, proliferative activity, and metabolic remodeling within gastric cancer tissues by influencing sialylation modifications. Furthermore, we identified the drug WZ35, which can inhibit the malignant proliferation of gastric cancer by targeting both sialic acid metabolism and sialylated protein modifications. We put forward a conjecture that the metabolism and modification of sialic acid promote the malignant development of gastric cancer, and we discovered that the drug WZ35 has an inhibitory effect on the sialic acid metabolism of gastric cancer.
GRAPHICAL ABSTRACT:
PMID:41870836 | PMC:PMC13009457 | DOI:10.1007/s13402-026-01194-6
PERMA: Benchmarking Personalized Memory Agents via Event-Driven Preference and Realistic Task Environments
A Synchronous EEG-fNIRS BCI: A Proof-of-Concept for Multimodal Avalanche Analysis of Motor Cognition in Older Adults
Mind Your HEARTBEAT! Claw Background Execution Inherently Enables Silent Memory Pollution
Targeting sialic acid metabolism: a therapeutic strategy against gastric cancer driven by WZ35
Cell Oncol (Dordr). 2026 Mar 23;49(2):60. doi: 10.1007/s13402-026-01194-6.
NO ABSTRACT
PMID:41870836 | DOI:10.1007/s13402-026-01194-6